Neurogene
NGNE
25.87
+0.42
+1.65%
Neurogene
US · NGNE
#3726 by market cap
25.87
+0.42
+1.65%
Live - 5344 symbols - heartbeat 204s ago
· 2026-10-08 09:19
Pre-market
29.12
+12.56%
After-hours
25.87
0.00%
Overnight
26.11
+0.93%
- Market cap
- 517.69M
- P/E (TTM)i
- -5.13
- P/Bi
- 2.38
- EPSi
- -4.24
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on NGNE?
Anonymous reader poll. Unscientific, not investment advice.
About Neurogene
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
- Founded
- 2007
- CEO
- Dr. Rachel McMinn, PhD
- Employees
- 131
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- neurogene.com
Company profile
- Exchange
- US
- Symbol
- NGNE
- Market-cap rank
- #3726
- Market cap
- 517.69M
- Float cap
- 292.33M
- Shares out
- 20.01M
- Float shares
- 11.30M
Sectors & themes
Biotechnology
Quote time 2026-10-08 09:19:45 · For reference only, not investment advice and not tailored to your situation.